ROLE OF ADJUVANT INTRAVESICAL CHEMOTHERAPY IN THE COMBINED ORGAN-SPARING TREATMENT OF NON-MUSCLE-INVASIVE BLADDER CANCER
https://doi.org/10.17650/1726-9776-2014-10-2-26-28
Abstract
Objective: to enhance the efficiency of combined treatment for non-muscle-invasive bladder cancer ((NMIBC) and to assess the results of its treatment using transurethral resection (TUR) as monotherapy and in combination with intravesical adjuvant chemotherapy (CT).
Subjects and methods. The results of treatment were analyzed in 59 patients with NMIBC. Twenty-two patients underwent TUR in Group 1; TUR and single intravesical injection of drugs were performed in 19 patients in Group 2; 18 patients had TUR and long-term intravesical CT.
Results and discussion. The recurrence rates were 59.1, 57.9, and 38.89 % in Groups 1, 2, and 3, respectively. Intravesical CT was found to appreciably affect the prevention of recurrence in the area of resection. The rate of this recurrence was 31.81, 26.32, and 5.56 % in Groups 1, 2, and 3, respectively.
Conclusion. Adjuvant intravesical chemotherapy CT is an effective method to prevent recurrent bladder cancer.
About the Authors
A. Yu. Zubko
Department of Urology, Kazan State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
I. R. Nuriev
Department of Urology, Kazan State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
E. N. Sitdykov
Department of Urology, Kazan State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Ok J.H., Mejers F.J., Evans C.P. Medical and surgical palliative care of patients with urological maligniancies. J Urol 2005;174(4 Pt 1):1177–82.
2. Злокачественные новообразования в России в 2010 году. Заболеваемость и смертность. Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М., 2012. 188 с.
3. Состояние онкологической помощи на-селению России в 2011. Под ред. В.И. Чис-сова, В.В. Старинского, Г.В. Петровой. М., 2012. 240 с.
4. Матвеев Б.П., Фигурин К.М., Карякин О.Б. Рак мочевого пузыря. М.: Вердана, 2001. 244 с.
5. Переверзев А.С., Петров С.Б. Опухоли мочевого пузыря. Харьков: Факт, 2002. 303 с.
6. Русаков И.Г., Быстров А.А. Хирургиче-ское лечение, химио- и иммунотерапия больных поверхностным раком мочевого пузыря. Практ онкол 2003;4:214–24.
7. Кудашев Б.В. Применение метода флуо-ресцентной диагностики для повышения радикализма трансуретральной резек-ции мочевого пузыря. Дис. … канд. мед.наук. М., 2001. 122 с.
8. Akbal С., Sozen S., Sokmensuer C. et al. Microstaging of pTl transitional cell carcinoma of the bladder. Congress of the European Association of Urology, Abstr. Geneva, 2001. P. 53.
9. Hall R.R. The role of transurethral surgery alone and with combined modality therapy. In: N.J. Vogelzang, P.T. Scardino, W.U. Shipley et al. Comprehensive textbook of genitourinary oncology. Baltimore: William & Wilkins,1996. P. 509–513.
10. Данильченко Д.И. Клиническая оценка и внедрение новых малоинвазивных мето-дов диагностики рака мочевого пузыря. Автореф. дис. … д-ра мед. наук. СПб., 2008.
11. Chopin D.K., Gattengo B. Superficial bladder cancer. Eur Urol 2002;42:533–41.
12. Malmstrom P.U. Improved patient outcomes with BCG immunotherapy vs. chemotherapy: Swedish and worldwide experience. Eur Urol 2000;37(Suppl 1):16–20.
Review
For citations:
Zubko A.Yu., Nuriev I.R., Sitdykov E.N. ROLE OF ADJUVANT INTRAVESICAL CHEMOTHERAPY IN THE COMBINED ORGAN-SPARING TREATMENT OF NON-MUSCLE-INVASIVE BLADDER CANCER. Cancer Urology. 2014;10(2):26-28. (In Russ.) https://doi.org/10.17650/1726-9776-2014-10-2-26-28
Views:
994
Email this article 